Targeted protein degradation (TPD) is a revolutionary approach to targeted therapy in
hematological malignancies that potentially circumvents many constraints of existing small …

Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that uses
the proteasome ubiquitin system to target proteins of interest and promote their degradation …

Abstract PROteolysis TArgeting Chimeras (PROTACs) degrade target proteins via the
ubiquitin-proteasome system, providing novel insights into drug development for …

Targeted therapies, such as small molecule kinase inhibitors, have made significant
progress in the treatment of hematologic malignancies by directly modulating protein activity …

Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that
utilize the ubiquitin proteasome system (UPS) to degrade proteins of interest (POI) …

Targeted protein degradation (TPD) is emerging as a strategy to overcome the limitations of
traditional small-molecule inhibitors. Proteolysis-targeting chimera (PROTAC) technology …

The fight to find effective, long-lasting treatments for cancer has led many researchers to
consider protein degrading entities. Recent developments in PROteolysis TArgeting …

Abstract PROteolysis Targeting Chimeras (PROTACs) are a family of heterobifunctional
small molecules that specifically target cellular proteins for degradation. Given that their …

Heterobifunctional protein degraders, such as PROteolysis TArgeting Chimera (PROTAC)
protein degraders, constitute a novel therapeutic modality that harnesses the cell's natural …

Simple Summary Proteostasis is a balance between protein formation and degradation. All
cells maintain their proteome throughout their lifespan. Malignant cells rely on protein …